Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 72
- Registration Number
- NCT05574881
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Target Recruit Count
- 120
- Registration Number
- NCT05429684
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
🇨🇳Jin Yang, Xi'an, Shaanxi, China
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Caigang Liu
- Target Recruit Count
- 136
- Registration Number
- NCT05426486
- Locations
- 🇨🇳
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China
A Study for the Adjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 2413
- Registration Number
- NCT05420467
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study for the Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 1576
- Registration Number
- NCT05420454
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 20
- Registration Number
- NCT05385705
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Conditions
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 53
- Registration Number
- NCT05325632
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Carey Anders, M.D.
- Target Recruit Count
- 48
- Registration Number
- NCT05323955
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-06-24
- Target Recruit Count
- 376
- Registration Number
- NCT05188313
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.